{"title":"Acetylcholine receptors antibodies in postural tachycardia syndrome","authors":"Jiawei Li, Qing-you Zhang, Junbao Du","doi":"10.14800/RCI.516","DOIUrl":null,"url":null,"abstract":"Postural tachycardia syndrome (POTS) is a type of chronic orthostatic intolerance. Acetylcholine receptor antibodies (AChR-ab) mediated autonomic dysfunction is common in POTS patients. Therefore, it is important to explore the value of serum AChR-ab in those patients. In a recent paper published in Pediatric Cardiology, we compared POTS patients with different AChR-ab status and found preceding infection, syncope and fatigue as main clinical features of POTS patients with AChR-ab positive. Thus, clinicians can determine targeted therapy of acetylcholinesterase inhibitors or immunotherapy according to both the specific clinical features and the results of AChR-ab detecting.","PeriodicalId":20980,"journal":{"name":"Receptors and clinical investigation","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Receptors and clinical investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14800/RCI.516","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Postural tachycardia syndrome (POTS) is a type of chronic orthostatic intolerance. Acetylcholine receptor antibodies (AChR-ab) mediated autonomic dysfunction is common in POTS patients. Therefore, it is important to explore the value of serum AChR-ab in those patients. In a recent paper published in Pediatric Cardiology, we compared POTS patients with different AChR-ab status and found preceding infection, syncope and fatigue as main clinical features of POTS patients with AChR-ab positive. Thus, clinicians can determine targeted therapy of acetylcholinesterase inhibitors or immunotherapy according to both the specific clinical features and the results of AChR-ab detecting.